What You Need to Know
• A new study found that GLP-1 drugs, like Ozempic and Wegovy, reduce long-term sick leave by 17%.
• The research indicates that using GLP-1 medications can save individuals approximately $866 annually in salary.
• In Denmark, where the study was conducted, sick leave policies differ significantly from those in the U.S.
Researchers from the National Bureau of Economic Research published a study this month indicating that GLP-1 drugs, prescribed for diabetes and obesity, can lead to significant cost savings for both employees and employers by reducing long-term sick leave. The study revealed that patients using these medications took 17% less sick leave lasting over 30 days compared to non-users. This reduction translates to savings of up to 1.5% of an individual’s salary, averaging around $866. The findings were based on data from Denmark, where sick leave policies require employers to pay full salaries for up to 30 days of illness, with the government covering longer absences.
Why It Matters
This study highlights the economic impact of GLP-1 medications on workforce productivity and healthcare costs. In Denmark, the structure of sick leave benefits allows for a clearer understanding of the fiscal implications of reduced absenteeism. While the findings suggest potential savings for the government, they also raise questions about how similar benefits could manifest in countries like the United States, where sick leave policies are less generous. Understanding these dynamics can inform discussions about healthcare policies and employee wellness initiatives globally.
Read the Full Story →
